Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Spesifisert narkotikabruksundersøkelse av Leqvio for s.c. Injeksjon.

13. november 2026 oppdatert av: Novartis Pharmaceuticals

Spesifisert narkotikabruksundersøkelse av Leqvio for s.c. Injeksjon (Familiær hyperkolesterolemi eller hyperkolesterolemi, CKJX839A11401)

The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

Uncontrolled, central registration system, multicenter, special drug use-results surveillance.

This is a prospective, open-label, multicenter, single-arm observational study (non-interventional study: NIS) conducted only in Japan.

The survey will include patients with familial hypercholesterolaemia or hypercholesterolaemia who have received treatment with Leqvio. Patients who discontinued treatment with Leqvio before completing the 24-month observation period will be followed for safety until the date of the last dose of Leqvio plus 180 days or until 24 months after the first dose of Leqvio, whichever comes earlier.

Studietype

Observasjonsmessig

Registrering (Faktiske)

585

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Akita, Japan, 0108577
        • Novartis Investigative Site
      • Chiba, Japan, 2610024
        • Novartis Investigative Site
      • Fukuoka, Japan, 8110213
        • Novartis Investigative Site
      • Fukushima, Japan, 9601295
        • Novartis Investigative Site
      • Himeji, Japan, 6711227
        • Novartis Investigative Site
      • Ishikawa, Japan, 9208641
        • Novartis Investigative Site
      • Kagoshima, Japan, 8920853
        • Novartis Investigative Site
      • Kumamoto, Japan, 8614193
        • Novartis Investigative Site
      • Kyoto, Japan, 6078062
        • Novartis Investigative Site
      • Nara, Japan, 6308581
        • Novartis Investigative Site
      • Okayama, Japan, 7008558
        • Novartis Investigative Site
      • Osaka, Japan, 5458586
        • Novartis Investigative Site
      • Osaka, Japan, 5438555
        • Novartis Investigative Site
      • Osaka, Japan, 5588558
        • Novartis Investigative Site
      • Shizuoka, Japan, 4228527
        • Novartis Investigative Site
    • Aichi-ken
      • Handa, Aichi-ken, Japan, 4750817
        • Novartis Investigative Site
      • Ichinomiya, Aichi-ken, Japan, 4918551
        • Novartis Investigative Site
      • Ichinomiya, Aichi-ken, Japan, 4940001
        • Novartis Investigative Site
      • Komaki, Aichi-ken, Japan, 4858520
        • Novartis Investigative Site
      • Nagoya, Aichi-ken, Japan, 4540933
        • Novartis Investigative Site
      • Nagoya, Aichi-ken, Japan, 4610045
        • Novartis Investigative Site
      • Toyoake, Aichi-ken, Japan, 4701192
        • Novartis Investigative Site
      • Tsushima, Aichi-ken, Japan, 4960038
        • Novartis Investigative Site
    • Chiba
      • Asahi, Chiba, Japan, 2892511
        • Novartis Investigative Site
      • Inzai, Chiba, Japan, 2701694
        • Novartis Investigative Site
      • Urayasu, Chiba, Japan, 2790021
        • Novartis Investigative Site
    • Ehime
      • Matsuyama, Ehime, Japan, 7918016
        • Novartis Investigative Site
    • Fukui
      • Fukui-shi, Fukui, Japan, 9108526
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japan, 8140180
        • Novartis Investigative Site
      • Fukuoka, Fukuoka, Japan, 8150082
        • Novartis Investigative Site
      • Kitakyushu, Fukuoka, Japan, 8078556
        • Novartis Investigative Site
      • Kitakyushu, Fukuoka, Japan, 8000031
        • Novartis Investigative Site
    • Fukushima
      • Fukushima, Fukushima, Japan, 9608611
        • Novartis Investigative Site
      • Kōriyama, Fukushima, Japan, 9638501
        • Novartis Investigative Site
      • Shirakawa, Fukushima, Japan, 9610005
        • Novartis Investigative Site
    • Gifu
      • Gifu, Gifu, Japan, 5008384
        • Novartis Investigative Site
    • Hiroshima
      • Hiroshima, Hiroshima, Japan, 7320053
        • Novartis Investigative Site
      • Kure, Hiroshima, Japan, 7370023
        • Novartis Investigative Site
    • Hokkaido
      • Asahikawa, Hokkaido, Japan, 0788211
        • Novartis Investigative Site
      • Asahikawa, Hokkaido, Japan, 0788214
        • Novartis Investigative Site
      • Sapporo, Hokkaido, Japan, 065-0027
        • Novartis Investigative Site
      • Sapporo, Hokkaido, Japan, 0040052
        • Novartis Investigative Site
      • Sapporo, Hokkaido, Japan, 0620003
        • Novartis Investigative Site
    • Hyōgo
      • Amagasaki, Hyōgo, Japan, 6608511
        • Novartis Investigative Site
      • Himeji, Hyōgo, Japan, 6708560
        • Novartis Investigative Site
      • Kobe, Hyōgo, Japan, 6540026
        • Novartis Investigative Site
      • Ono, Hyōgo, Japan, 6751327
        • Novartis Investigative Site
      • Takarazuka, Hyōgo, Japan, 6650873
        • Novartis Investigative Site
    • Ibaraki
      • Kamisu, Ibaraki, Japan, 3140146
        • Novartis Investigative Site
      • Koga, Ibaraki, Japan, 3060232
        • Novartis Investigative Site
      • Mito, Ibaraki, Japan, 3100015
        • Novartis Investigative Site
      • Moriya, Ibaraki, Japan, 3020102
        • Novartis Investigative Site
      • Tsukuba, Ibaraki, Japan, 3058576
        • Novartis Investigative Site
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 8908760
        • Novartis Investigative Site
    • Kanagawa
      • Fujisawa, Kanagawa, Japan, 2520802
        • Novartis Investigative Site
      • Yokohama, Kanagawa, Japan, 2248503
        • Novartis Investigative Site
      • Yokohama, Kanagawa, Japan, 2350016
        • Novartis Investigative Site
      • Yokosuka, Kanagawa, Japan, 2398567
        • Novartis Investigative Site
      • Yokosuka, Kanagawa, Japan, 2400101
        • Novartis Investigative Site
    • Kumamoto
      • Yatsushiro, Kumamoto, Japan, 8668533
        • Novartis Investigative Site
    • Kyoto
      • Kyoto, Kyoto, Japan, 6028566
        • Novartis Investigative Site
      • Kyoto, Kyoto, Japan, 6128555
        • Novartis Investigative Site
      • Kyōtanabe, Kyoto, Japan, 6100334
        • Novartis Investigative Site
    • Mie-ken
      • Tsu, Mie-ken, Japan, 5148507
        • Novartis Investigative Site
    • Nagasaki
      • Nagasaki, Nagasaki, Japan, 8508555
        • Novartis Investigative Site
      • Nagasaki, Nagasaki, Japan, 8528055
        • Novartis Investigative Site
      • Ōmura, Nagasaki, Japan, 8568562
        • Novartis Investigative Site
    • Nara
      • Ikoma, Nara, Japan, 6360802
        • Novartis Investigative Site
      • Kashihara, Nara, Japan, 6340045
        • Novartis Investigative Site
      • Tenri, Nara, Japan, 6328552
        • Novartis Investigative Site
    • Niigata
      • Nagaoka, Niigata, Japan, 9408621
        • Novartis Investigative Site
    • Oita Prefecture
      • Ōita, Oita Prefecture, Japan, 8700263
        • Novartis Investigative Site
      • Ōita, Oita Prefecture, Japan, 8701133
        • Novartis Investigative Site
      • Ōita, Oita Prefecture, Japan, 8797761
        • Novartis Investigative Site
    • Okayama-ken
      • Kurashiki, Okayama-ken, Japan, 7108602
        • Novartis Investigative Site
    • Okinawa
      • Urasoe, Okinawa, Japan, 9012102
        • Novartis Investigative Site
      • Uruma, Okinawa, Japan, 9042293
        • Novartis Investigative Site
    • Osaka
      • Izumisano, Osaka, Japan, 5988577
        • Novartis Investigative Site
      • Moriguchi, Osaka, Japan, 5708507
        • Novartis Investigative Site
      • Osaka, Osaka, Japan, 5400006
        • Novartis Investigative Site
      • Osaka, Osaka, Japan, 5430042
        • Novartis Investigative Site
      • Takatsuki, Osaka, Japan, 5698686
        • Novartis Investigative Site
      • Takatsuki, Osaka, Japan, 5690852
        • Novartis Investigative Site
      • Takatsuki, Osaka, Japan, 5691121
        • Novartis Investigative Site
      • Toyonaka, Osaka, Japan, 5600083
        • Novartis Investigative Site
    • Saitama
      • Asaka, Saitama, Japan, 3510021
        • Novartis Investigative Site
      • Gyōda, Saitama, Japan, 3610056
        • Novartis Investigative Site
      • Iruma-gun, Saitama, Japan, 3500495
        • Novartis Investigative Site
      • Kitamoto, Saitama, Japan, 3648501
        • Novartis Investigative Site
      • Sōka, Saitama, Japan, 3400043
        • Novartis Investigative Site
      • Tokorozawa, Saitama, Japan, 3591142
        • Novartis Investigative Site
    • Shiga
      • Nagahama, Shiga, Japan, 5268580
        • Novartis Investigative Site
    • Shizuoka
      • Izunokuni, Shizuoka, Japan, 4102295
        • Novartis Investigative Site
    • Tochigi
      • Mooka, Tochigi, Japan, 3214306
        • Novartis Investigative Site
    • Tokyo
      • Hachiōji, Tokyo, Japan, 1920918
        • Novartis Investigative Site
      • Machida, Tokyo, Japan, 1940021
        • Novartis Investigative Site
      • Meguro City, Tokyo, Japan, 1538515
        • Novartis Investigative Site
      • Minato, Tokyo, Japan, 1060031
        • Novartis Investigative Site
      • Nerima-ku, Tokyo, Japan, 1768530
        • Novartis Investigative Site
      • Shinjuku, Tokyo, Japan, 1608488
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Japan, 1628666
        • Novartis Investigative Site
      • Sumida City, Tokyo, Japan, 1308575
        • Novartis Investigative Site
      • Toshima-ku, Tokyo, Japan, 1710014
        • Novartis Investigative Site
    • Toyama
      • Takaoka, Toyama, Japan, 9391104
        • Novartis Investigative Site
    • Wakayama
      • Hashimoto, Wakayama, Japan, 6480005
        • Novartis Investigative Site
    • Yamagata
      • Sakata, Yamagata, Japan, 9988501
        • Novartis Investigative Site
      • Yamagata, Yamagata, Japan, 9909585
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

15 år til 100 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients treated with inclisiran

Beskrivelse

Inclusion Criteria:

  • Patients who provided written informed consent to participate in this survey prior to the start of treatment with Leqvio.
  • Patients who received treatment with Leqvio as per the package insert.

Exclusion Criteria:

  • Patients who received treatment with a formulation containing the same ingredients as Leqvio in the past.
  • Patients participating in other interventional studies at the time of informed consent.
  • Patients planning to participate in other interventional studies during this survey.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
inclisiran

Patients prescribed with inclisiran

Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of patients with adverse events
Tidsramme: Up to 24 months

To evaluate the long-term safety profile of Leqvio

Up to 24 months
Numbers of patients with serious adverse events, adverse events by severity, and adverse drug reactions
Tidsramme: Up to 24 months

To evaluate the long-term safety profile of Leqvio

Up to 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of patients with adverse events leading to discontinuation of treatment with the product
Tidsramme: Up to 24 months

To evaluate the tolerability of Leqvio

Up to 24 months
Percent change from baseline in LDL-C levels
Tidsramme: Month 24

To evaluate the efficacy of Leqvio based on LDL-C levels

Month 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. mars 2024

Primær fullføring (Faktiske)

1. november 2026

Studiet fullført (Faktiske)

1. november 2026

Datoer for studieregistrering

Først innsendt

16. februar 2024

Først innsendt som oppfylte QC-kriteriene

16. februar 2024

Først lagt ut (Faktiske)

23. februar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere